Characterization of the phospholipidogenic potential of 4(1H)-pyridone antimalarial derivatives

Toxicology in Vitro

Volumn 23, Issue 8, 2009, Pages 1528-1534

  Almela, María Jesús ^a   Torres, Pedro Alfonso ^a   Lozano, Sonia ^a   Herreros, Esperanza ^a  

^a GLAXOSMITHKLINE   (Spain)

Author keywords

Antimalarials; HepG2; In vitro; NBD PE; Phospholipidosis

Indexed keywords

4 PYRIDONE DERIVATIVE; AMITRIPTYLINE; AZITHROMYCIN; CHLOROQUINE; DACTINOMYCIN; DOXORUBICIN; FLUORESCENT DYE; ISONIAZID; KETOCONAZOLE; OFLOXACIN; PARACETAMOL; RIFAMPICIN; TAMOXIFEN;

ARTICLE; CELL ASSAY; CELL STRAIN HEPG2; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPIDOSIS; MAXIMUM ALLOWABLE CONCENTRATION; PHOSPHOLIPID SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ANTIMALARIALS; CELL SURVIVAL; HEP G2 CELLS; HUMANS; LYSOSOMES; PHOSPHATIDYLETHANOLAMINES; PHOSPHOLIPIDS; PYRIDONES; SOLUBILITY;

PLASMODIUM FALCIPARUM;

EID: 70350712410     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2009.06.015     Document Type: Article

References (21)

1. Anderson N., and Borlak J. Drug-induced phospholipidosis. FEBS Letters 580 (2006) 5533-5540
2. Bonanomi M., Dantas N.C., and Medeiros F.A. Retinal nerve fibre layer thickness measurements in patients using chloroquine. Clinical and Experimental Ophthalmology 34 (2006) 130-136
3. Casartelli A., Bonato M., Cristofori P., Crivellente F., Dal Negro G., Masotto I., Mutinelli C., Valko K., and Bonfante V. A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development. Cell Biology and Toxicology 19 (2003) 161-176
4. Evans S.M., Casartelli A., Herreros E., Minnick D.T., Day C., George E., and Westmorelan C. Development of a high throughput in vitro toxicity screen predictive of high acute in vivo toxic potential. Toxicology in Vitro 15 (2001) 579-584
5. Fujimura H., Dekura E., Kurabe M., Shimazu N., Koitabashi M., and Toriumi W. Cell-based fluorescence assay for evaluation of new-drugs potential for phospholipidosis in an early stage of drug development. Experimental and Toxicologic Pathology 58 (2007) 375-382
6. Guigui B., Perrot S., Berry J.P., Fleury-Feith J., Martin N., Metreau J.M., Dhumeaux D., and Zafrani E.S. Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease. Hepatology 8 (1988) 1063-1068
7. Halliwell W.H. Cationic amphiphilic drug-induced phospholipidosis. Toxicologic Pathology 25 (1997) 53-60
8. Herreros E., Almela M.J., Lozano S., Roncales M.C., Torres P., Gut J., Rosenthal P.J., Gómez de las Heras F.M., Pompliano D.L., and Gargallo-Viola D. In vitro antimalarial activity of 4(1 H)-pyridone derivatives. American Journal of Tropical and Medicine Hygiene Suppl. 6 (2005) 73 (p. 117) (Program and Abstracts of the 54th Annual Meeting of the ASTMH)
9. Kasahara T., Tomita K., Murano H., Harada T., Tsubakimoto K., Ogihara T., Ohnishi S., and Kakinuma C. Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential. Toxicological Sciences 90 1 (2006) 133-141
10. Kodavanti U.P., and Mehendale H.M. Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacological Reviews 42 (1990) 327-354
11. Lullmann H., Lullmann-Rauch R., and Wassermann O. Lipidosis induced by amphiphilic cationic drugs. Biochemical Pharmacology 27 (1978) 1103-1108
12. Monteith D.K., Morgan R.E., and Halstead B. In vitro assays and biomarkers for drug induced phospholipidosis. Expert Opinion on Drug Metabolism and Toxicology 2 5 (2006) 687-696
13. Morelli J.K., Buehrle M.m., Pognan F., Barone L.R., Fieles W., and Ciaccio P.J. Validation of an in vitro screen for phospholipidosis using a high-content biology platform. Cell Biology and Toxicology 22 (2006) 15-27
14. Nioi P., Perry B.K., Wang E., Gu Y., and Snyder R.D. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipids-based methodologies. Toxicological Sciences 99 1 (2007) 162-173
15. Reasor M.J. A review of the biology and toxicologic implications of the induction of lysosomal lamellar bodies by drugs. Toxicology and Applied Pharmacology 97 (1989) 47-56
16. Reasor M.J., Hastings K.L., and Ulrich R.G. Drug-induced phospholipidosis: issues and future directions. Expert Opinion on Drug Safety 5 (2006) 567-583
17. Sawada H., Takami K., and Asahi S. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicological Sciences 83 (2005) 282-292
18. Ulrich R.G., Kilgore K.S., Sun E.L., Cramer C.T., and Ginsberg L.C. An in vitro fluorescence assay for the detection of drug induced cytoplasmic lamellar bodies. Toxicology Methods 1 (1991) 89-105
19. Vestergaard L.S., and Ringwald P. Responding to the challenge of antimalarial drug resistance by routine monitoring to update national malaria treatment policies. American Journal of Tropical and Medicine Hygiene 77 Suppl. 6 (2007) 153-159
20. Yano B.L., Bond D.M., Novilla M.N., McFadden L.G., and Reasor M.J. Spinosad insecticide: subchronic and chronic toxicity and lack of carcinogenicity in Fischer 344 rats. Toxicological Sciences 65 (2002) 288-298
21. Yeates C.L., Batchelor J.F., Capon E.C., Cheesman N.J., Fry M., Hudson A.T., Pudney M., Trimming H., Woolven J., Bueno J.M., Chicharro J., Fernández E., Fiandor J.M., Gargallo-Viola D., Gómez de las Heras F., Herreros E., and León M.L. Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials. Journal of Medicinal Chemistry 51 (2008) 2845-2852